We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback